Synovial Fibroblast 1: Secretion response of primary human synovial fibroblast samples from one healthy and one rheumatoid arthritis donor to a panel of 10 stimuli and 10 small molecule inhibitors - Dataset (ID:20233)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N2586 | Lestaurtinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | MCP-1 (MCAF) | 6775.0 | 73 | |
| N2586 | Ruxolitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | MCP-1 (MCAF) | 7049.0 | 71 | |
| N2586 | Tofacitinib | 0.3 | uM | Adiponectin | 5 | ng/mL | 3 | MCP-1 (MCAF) | 5125.5 | 62 | |
| N2586 | IKK16 | 2.0 | uM | Adiponectin | 5 | ng/mL | 3 | MCP-1 (MCAF) | 3448.5 | 80 | |
| RA2159 | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 2938.0 | 73 | ||||
| RA2159 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 1988.0 | 85 | |
| RA2159 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 2415.0 | 77 | |
| RA2159 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 3167.5 | 68 | |
| RA2159 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 3120.0 | 67 | |
| RA2159 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 1334.5 | 70 | |
| RA2159 | 3 | MCP-1 (MCAF) | 4044.0 | 73 | |||||||
| N2586 | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 7956.0 | 63 | ||||
| N2586 | PD184352 | 0.1 | uM | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 7796.0 | 65 | |
| N2586 | Lestaurtinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 6123.5 | 70 | |
| N2586 | Ruxolitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 7545.0 | 88 | |
| N2586 | Tofacitinib | 0.3 | uM | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 5705.0 | 83 | |
| N2586 | IKK16 | 2.0 | uM | IGF-I | 100 | ug/mL | 3 | MCP-1 (MCAF) | 3211.0 | 74 | |
| N2586 | 3 | MCP-1 (MCAF) | 7555.5 | 84 | |||||||
| RA2159 | EGF | 100 | ng/mL | 3 | MCP-1 (MCAF) | 3417.5 | 90 | ||||
| RA2159 | PD184352 | 0.1 | uM | EGF | 100 | ng/mL | 3 | MCP-1 (MCAF) | 2416.0 | 77 | |
| RA2159 | Lestaurtinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | MCP-1 (MCAF) | 4368.0 | 77 | |
| RA2159 | Ruxolitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | MCP-1 (MCAF) | 4297.5 | 60 | |
| RA2159 | Tofacitinib | 0.3 | uM | EGF | 100 | ng/mL | 3 | MCP-1 (MCAF) | 3491.0 | 71 | |
| RA2159 | IKK16 | 2.0 | uM | EGF | 100 | ng/mL | 3 | MCP-1 (MCAF) | 1360.0 | 54 | |
| RA2159 | JNK-IN-11 | 0.3 | uM | 3 | MCP-1 (MCAF) | 2301.5 | 80 |